PHASE-II TRIAL OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-M-ANISIDIDE (AMSA) IN THE TREATMENT OF ADVANCED NON-HODGKINS LYMPHOMA
- 1 January 1980
- journal article
- research article
- Vol. 64 (10-1) , 1157-1158
Abstract
A disease-oriented trial of 4''-(9-acridinylamino)methanesulfon-m-anisidide) given once every 3 wk was undertaken in patients with advanced non-Hodgkin''s lymphoma. None of 15 adequately treated patients achieved complete or partial remissions. Toxicity was mild-to-moderate, consisting of myelosuppression (principally granulocytopenia) and malaise. The lack of any major responses in this number of patients suggests that in this schedule the drug is not useful in therapy for advanced non-Hodgkin''s lymphoma.This publication has 3 references indexed in Scilit:
- PHASE-I EVALUATION OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-META-ANISIDIDE (AMSA) BY A WEEKLY IV DOSE SCHEDULE1980
- INTERACTION OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-M-ANISIDIDE WITH DNA AND INHIBITION OF ONCORNAVIRUS REVERSE-TRANSCRIPTASE AND CELLULAR NUCLEIC-ACID POLYMERASES1978
- PHASE-1 CLINICAL INVESTIGATION OF 4'-(9-ACRIDINYLAMINO)METHANESULFON-M-ANISIDIDE (NSC 249992), A NEW ACRIDINE DERIVATIVE1978